首页 | 本学科首页   官方微博 | 高级检索  
     


Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects
Authors:Khan Sharun  Ruchi Tiwari  Mohd. Iqbal Yatoo  Shailesh Kumar Patel  Senthilkumar Natesan  Jaideep Dhama
Affiliation:1. Division of Surgery, ICAR-Indian Veterinary Research Institute , Izatnagar, Uttar Pradesh, India "ORCIDhttps://orcid.org/0000-0003-1040-3746;2. Department of Veterinary Microbiology and Immunology, College Of Veterinary Sciences, UP Pandit Deen Dayal Upadhayay Pashu Chikitsa Vigyan Vishwavidyalay Evum Go-Anusandhan Sansthan (DUVASU) , Mathura, Uttar Pradesh, India "ORCIDhttps://orcid.org/0000-0001-6897-3472;3. Division of Veterinary Clinical Complex, Faculty of Veterinary Sciences and Animal Husbandry, Shuhama, Alusteng Srinagar, Sher-E-Kashmir University of Agricultural Sciences and Technology of Kashmir , Srinagar, Jammu and Kashmir, India "ORCIDhttps://orcid.org/0000-0002-4501-7354;4. Division of Pathology, ICAR-Indian Veterinary Research Institute , Izatnagar, Uttar Pradesh, India;5. Department of Infectious Diseases, Indian Institute of Public Health Gandhinagar , Gandhinagar, Gujarat, India;6. Department of Ophthalmology, Tara Hospital , New Delhi, India
Abstract:ABSTRACT

Introduction

Coronavirus disease 2019 (COVID-19) has spread to several countries globally. Currently, there is no specific drug or vaccine available for managing COVID-19. Antibody-based immunotherapeutic strategies using convalescent plasma, monoclonal antibodies (mAbs), neutralizing antibodies (NAbs), and intravenous immunoglobulins have therapeutic potential.
Keywords:COVID-19  SARS-CoV-2  coronavirus  immunotherapeutics  immunoglobulin  convalescent plasma  neutralizing antibodies  monoclonal antibodies
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号